Author

Shoichi Kuyama

Observed names: Kuyama, Shoichi, S. Kuyama, SHOICHI KUYAMA

Institutions: Iwakuni Medical Center, National Hospital Organization

Observed institutions: Okayama University, Okayama University Hospital, Chugoku Central Hospital, Iwakuni Medical Center, National Hospital Organization, Shikoku Cancer Center, National Hospital Organization Minami-Okayama Medical Center

ORCID: 0000-0002-6079-3511

Observed ORCID: 0000-0002-6079-3511

OpenAlex ID: A5070015883

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

2019 · Luis Paz-Ares, Mikhail Dvorkin, et al. · The Lancet · 2,281

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

2020 · Jonathan W Goldman, Mikhail Dvorkin, et al. · The Lancet Oncology · 688

Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study

2024 · Luis G. Paz-Ares, Oscar Juan-Vidal, et al. · Journal of Clinical Oncology · 138

PDF

Phase II Trial of Gefitinib in Combination with Bevacizumab as First-Line Therapy for Advanced Non–Small Cell Lung Cancer with Activating EGFR Gene Mutations: The Okayama Lung Cancer Study Group Trial 1001

2015 · Eiki Ichihara, Katsuyuki Hotta, et al. · Journal of Thoracic Oncology · 104

Comparison of the Incidence and Pattern of Interstitial Lung Disease During Erlotinib and Gefitinib Treatment in Japanese Patients with Non-small Cell Lung Cancer: The Okayama Lung Cancer Study Group Experience

2010 · Katsuyuki Hotta, Katsuyuki Kiura, et al. · Journal of Thoracic Oncology · 72

PDF

A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid)

2022 · Akira Sugimoto, Shingo Matsumoto, et al. · Clinical Cancer Research · 71

The CLIP1–LTK fusion is an oncogenic driver in non‐small‐cell lung cancer

2021 · Hiroki Izumi, Shingo Matsumoto, et al. · Nature · 71

A Phase II Trial of Erlotinib Monotherapy in Pretreated Patients with Advanced Non-small Cell Lung Cancer Who Do Not Possess Active EGFR Mutations: Okayama Lung Cancer Study Group Trial 0705

2010 · Hiroshige Yoshioka, Katsuyuki Hotta, et al. · Journal of Thoracic Oncology · 68

PDF

Impact of HER2 Gene and Protein Status on the Treatment Outcome of Cisplatin-Based Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer

2008 · Shoichi Kuyama, Katsuyuki Hotta, et al. · Journal of Thoracic Oncology · 55

Phase II Study of Amrubicin Combined with Carboplatin for Thymic Carcinoma and Invasive Thymoma: North Japan Lung Cancer Group Study 0803

2014 · Akira Inoue, Shunichi Sugawara, et al. · Journal of Thoracic Oncology · 43

PDF

A Prospective Cohort Study to Define the Clinical Features and Outcome of Lung Cancers Harboring HER2 Aberration in Japan (HER2-CS STUDY)

2019 · Kiichiro Ninomiya, Tae Hata, et al. · CHEST Journal · 41

Large-Scale Clinico-Genomic Profile of Non-Small Cell Lung Cancer with KRAS G12C: Results from LC-SCRUM-Asia Study

2022 · Yutaro Tamiya, Shingo Matsumoto, et al. · Lung Cancer · 39

Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non–Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834

2025 · Satoru Miura, Hiroshi Tanaka, et al. · Journal of Clinical Oncology · 34

A phase II study of cisplatin plus S-1 with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer: The Okayama Lung Cancer Study Group Trial 0501

2014 · Naoyuki Nogami, Nagio Takigawa, et al. · Lung Cancer · 32

A new risk-assessment tool for venous thromboembolism in advanced lung cancer: a prospective, observational study

2022 · Yukari Tsubata, Takamasa Hotta, et al. · Journal of Hematology & Oncology · 25

PDF

Phase II study of S-1 in patients with previously-treated invasive thymoma and thymic carcinoma: North Japan lung cancer study group trial 1203

2019 · Yoko Tsukita, Akira Inoue, et al. · Lung Cancer · 25

A phase I trial of afatinib and bevacizumab in chemo-naïve patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404

2017 · Takashi Ninomiya, Naoyuki Nogami, et al. · Lung Cancer · 25

Comprehensive assessment of PD-L1 expression, tumor mutational burden and oncogenic driver alterations in non-small cell lung cancer patients treated with immune checkpoint inhibitors

2021 · Kiyotaka Yoh, Shingo Matsumoto, et al. · Lung Cancer · 24

Identification of risk factors for venous thromboembolism and validation of the Khorana score in patients with advanced lung cancer: based on the multicenter, prospective Rising-VTE/NEJ037 study data

2022 · Yukari Tsubata, Keita Kawakado, et al. · International Journal of Clinical Oncology · 22

PDF

Desire for Information and Involvement in Treatment Decisions: Lung Cancer Patients' Preferences and Their Physicians' Perceptions: Results from Okayama Lung Cancer Study Group Trial 0705

2010 · Katsuyuki Hotta, Katsuyuki Kiura, et al. · Journal of Thoracic Oncology · 22

Phase 2 Study of Afatinib Alone or Combined With Bevacizumab in Chemonaive Patients With Advanced Non–Small-Cell Lung Cancer Harboring EGFR Mutations: AfaBev-CS Study Protocol

2018 · Takashi Ninomiya, Nobuhisa Ishikawa, et al. · Clinical Lung Cancer · 21

TROPION-Lung07: Phase III study of Dato-DXd + pembrolizumab ± platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancer

2024 · Isamu Okamoto, Shoichi Kuyama, et al. · Future Oncology · 20

Clinical Outcomes of Second-Line Chemotherapy in Patients with Previously Treated Advanced Thymic Carcinoma: A Retrospective Analysis of 191 Patients from the NEJ023 Study

2019 · Kazunari Tateishi, Ryo Ko, et al. · The Oncologist · 20

A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or extensive-disease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401

2011 · Naoyuki Nogami, Katsuyuki Hotta, et al. · Lung Cancer · 19

PDF

A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027

2021 · Yuji Minegishi, Ou Yamaguchi, et al. · BMC Cancer · 18

PDF

Works count: 217

Citation count: 4,481

H-index: 21

I10-index: 41